Abstract
Among patients with atherosclerotic cardiovascular disease and LDL cholesterol levels of less than 70 mg per deciliter (1.81 mmol per liter), there was no incremental clinical benefit from the addition of niacin to statin therapy during a 36-month follow-up period, despite significant improvements in HDL cholesterol and triglyceride levels. (Funded by the National Heart, Lung, and Blood Institute and Abbott Laboratories; AIM-HIGH ClinicalTrials.gov number, NCT00120289.).
Keywords
SimvastatinNiacinMedicineStatinCholesterolResidual riskInternal medicineLipoproteinEndocrinologyCardiology
Related Publications
Ten-Year Mortality from Cardiovascular Disease in Relation to Cholesterol Level among Men with and without Preexisting Cardiovascular Disease
To determine the associations of total, low-density lipoprotein (LDL), and high-density lipoprotein (HDL) cholesterol with mortality from coronary heart disease and cardiovascul...
Comparison of Once-Daily, niacin Extended-Release/lovastatin with standard doses of atorvastatin and simvastatin (the advicor versus other Cholesterol-Modulating agents trial evaluation [ADVOCATE])
This study compared the relative efficacy of a once-daily niacin extended-release (ER)/lovastatin fixed-dose combination with standard doses of atorvastatin or simvastatin, with...
Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
In a randomized, double-blind five-year trial, we tested the efficacy of simultaneously elevating serum levels of high-density lipoprotein (HDL) cholesterol and lowering levels ...
Physical activity and lipoprotein metabolism: epidemiological evidence and clinical trials.
Prospective epidemiological studies have proven a close link between the lipoprotein profile and cardiovascular morbidity and mortality. As physical activity is accepted as a si...
Lipoprotein profile in men with peripheral vascular disease. Role of intermediate density lipoproteins and apoprotein E phenotypes.
BACKGROUND The role of lipoprotein disturbances in the development of peripheral vascular disease (PVD) has not been sufficiently clarified. METHODS AND RESULTS The relations am...
Publication Info
- Year
- 2011
- Type
- article
- Volume
- 365
- Issue
- 24
- Pages
- 2255-2267
- Citations
- 2850
- Access
- Closed
External Links
Social Impact
Altmetric
PlumX Metrics
Social media, news, blog, policy document mentions
Citation Metrics
2850
OpenAlex
Cite This
(2011).
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy.
New England Journal of Medicine
, 365
(24)
, 2255-2267.
https://doi.org/10.1056/nejmoa1107579
Identifiers
- DOI
- 10.1056/nejmoa1107579